PMC7365939_01
Comparison of chest CT scan between before and after treatment for the first patient. (A1) Chest CT scan showing enlarged lymph nodes in the retroperitoneum and mediastinum in postoperative re-examination. (A2) Chest CT showing that the enlarged lymph nodes in the retroperitoneum and mediastinum shrank or became loosened after 6 weeks of anlotinib combined chemoradiotherapy. CT, computed tomography; PD, progressive disease; PR, partial progressive disease.
fonc-10-00995-g0014.jpg
PMC7365939_01_fonc-10-00995-g0014.jpg
F14
Chest computed tomography (CT) scanning of on postoperative September 3, 2018, showed a thickened esophageal wall in the left upper lobe and surgical anastomosis as well as multiple enlarged LNs in the supraclavicular region, retroperitoneum, and mediastinum (Figure 14). After 6 weeks, chest CT of the treated area revealed that the enlarged LNs in the retroperitoneum and mediastinum shrank or became loosened with an outcome partial response (PR) (Figure 14).
PMC7365939_02
Comparison of chest CT scan between before and after treatment for the second patient. (B1) Chest CT showing that thickened esophageal wall and the enlarged lymph nodes in the mediastinum with an outcome of PD after patient underwent four cycles of chemotherapy. (B2) Chest CT scan representing that the primary tumor mass reduced in size and the enlarged lymph nodes in the mediastinum shrank or became loosened with an outcome of PR after anlotinib combined with radiotherapy and two cycles of chemotherapy. CT, computed tomography; PD, progressive disease; PR, partial progressive disease.
fonc-10-00995-g0015.jpg
PMC7365939_02_fonc-10-00995-g0015.jpg
F15
Chest CT scan on July 8, 2019, revealed an outcome of progressive disease (PD) (Figure 15). August 19, 2019. After 6 weeks, chest CT of the treated area revealed that the primary tumor mass reduced in size and the enlarged LNs in the mediastinum shrank or became loosened with an outcome of PR (Figure 15).